eli lilly - Search News

Eli Lilly shares drop

Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.

Investopedia on MSN · 11h

Watch These Eli Lilly Price Levels as Stock Slumps on Tepid Sales Outlook

Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant lowered its 2024 full-year forecast. Monitor these key price levels.

Reuters on MSN · 23h

Lilly forecasts weak fourth-quarter sales of weight-loss drug, shares slump

Eli Lilly forecast sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street estimates in the fourth quarter, sending the drugmaker's shares down more than 8% on Tuesday.

Eli Lilly acquires cancer program from Scorpion Therapeutics

Reuters · 2d

Eli Lilly to buy Scorpion Therapeutics' cancer therapy for up to $2.5 billion

Eli Lilly said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of cancer treatments.

The Wall Street Journal on MSN · 2d

Eli Lilly to Buy Scorpion Therapeutics Drug Program in $2.5 Billion Deal

Eli Lilly agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash.

MT Newswires on MSN · 1d

Eli Lilly to Acquire Scorpion Therapeutics' Breast Cancer Candidate For up to $2.5 Billion

Eli Lilly (LLY) agreed to acquire an experimental treatment for breast cancer and other advanced solid tumors from Scorpion Therapeutics for up to $2.5 billion. The purchase price includes an upfront payment and subsequent amounts that Scorpion's shareholders would receive as certain regulatory and sales milestones are achieved.

Drops for Lilly and Big Tech Weigh on Wall Street, Even

Newsable Asianet News on MSN · 1h

Eli Lilly Gets Wall Street Backing After Tuesday’s Turmoil, Stock Rises Premarket As Retail Stays Bullish

Eli Lilly & Co. (LLY) shares rose 0.3% premarket Wednesday, bouncing slightly after Tuesday's steep 6% plunge — the worst session for the stock in nearly four years. The selloff followed the drugmaker's disappointing fourth-quarter (Q4) revenue guidance,

Houston Chronicle · 16h

Stock market today: Wall Street mostly rises after encouraging inflation data despite Lilly's drag

Stocks got a boost from a report showing inflation at the U.S. wholesale level wasn’t as high last month as economists expected. It’s an encouraging signal ahead of a report coming Wednesday, which will show how much inflation U.

U.S. News & World Report · 1d

Stock Market Today: Drops for Lilly and Big Tech Weigh on Wall Street, Even as Most Stocks Rise

Drops for Lilly and Big Tech Weigh on Wall Street, Even as Most Stocks Rise NEW YORK (AP) — Drops for Eli Lilly and other influential companies are weighing on U.S. indexes Tuesday, even though most of the market is rising following an encouraging update on inflation.

Has Eli Lilly Stock Peaked?

Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...

Pharmaceutical Technology3h

JP Morgan 2025: Eli Lilly misses 2024 revenue estimate by $400m

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

Eli Lilly & Co: Strong Growth Prospects and Strategic Positioning Justify Buy Rating

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...

21h

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...

BioSpace2h

JPM25 Day Two: Roche, Amgen, Merck, Lilly and Biogen

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...

Eli Lilly & Co.: Positive Long-Term Outlook Despite Recent Setbacks – Buy Rating Affirmed

Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at ...

23h

6LLY : Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5...

Eli Lilly expects 2024 revenue of $45.0 billion, reflecting a 32% increase, with strong contributions from Mounjaro and ...

FiercePharma15h

JPM25: Eli Lilly's preliminary '24 sales figures show a continued easing in breakneck GLP-1 market

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

1hon MSN

These Stocks Are Moving the Most Today: JPMorgan, Wells Fargo, BlackRock, Eli Lilly, D-Wave Quantum, and More

Shares of Wells Fargo rose 3.9% after the San Francisco bank’s fourth-quarter profit of $1.43 a share beat expectations of $1 ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Eli Lilly shares drop

Eli Lilly acquires cancer program from Scorpion Therapeutics

Drops for Lilly and Big Tech Weigh on Wall Street, Even

Related topics